GERMANY REGENERATIVE MEDICINE NOT BEING COMMERCIALISED SAY EXPERTS
May 1st, 2007
BY KEITH NUTHALLALTHOUGH Germany is a leading player in developing regenerative medicine, it must do more to remove administrative and business barriers preventing useful research being commercialised a report published by the German Ministry for Education and Research has claimed. Treatments such as skin replacement products for chronic wounds, cell therapy liver repairs, and repairing bone defects could be worth Euro 150 million annually in a few years, predicted the report's authors, consultants Capgemini. Their study has found that while Germany "has done the ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.